Alveus debuts in obesity arena with $160m Series A
Alveus Therapeutics has debuted with $160m in Series A financing, as the biotech looks to join the crowded obesity sector…
09 Jan 2026
J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts
Johnson & Johnson (J&J) has become the latest in a stream of pharma companies to sign a drug pricing deal with the US government under President Donald Trump’s Most Favored…
09 Jan 2026
Takeda and Halozyme sign global agreement for Enhanze technology
Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter’s Enhanze drug delivery technology. Through this partnership, Takeda aims to enhance patient…
09 Jan 2026
Santhera grants Agamree rights to Nxera for DMD
Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD) in Australia, Japan, New Zealand, and South Korea. Agamree is…
08 Jan 2026
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
Eli Lilly has agreed to acquire autoimmune oral drug developer Ventyx Biosciences, representing the big pharma company’s latest push to diversify its pipeline beyond blockbuster diabetes and obesity products. Lilly…
08 Jan 2026
GSK to file for approval of twice-yearly hep B drug on positive Phase III data
GSK’s six-monthly triple-action investigational antisense oligonucleotide (ASO) candidate has demonstrated a clinically and statistically significant functional cure in chronic hepatitis B in two Phase III trials. The B-Well 1 (NCT05630807)…
08 Jan 2026
Octapharma receives FDA approval for new Fibryga formulation in AFD
Octapharma has received approval from the US Food and Drug Administration (FDA) for a new 2-gram (g) formulation of Fibryga for use in patients with acquired fibrinogen deficiency (AFD). The…